Chemours Co experienced a significant decline of 9.03%, hitting a 5-day low. This drop comes amid broader market weakness, with the Nasdaq-100 down 0.41% and the S&P 500 down 0.05%. The stock's movement suggests sector rotation as investors react to the overall market conditions.
The decline is attributed to sector rotation, as the stock moves in response to the negative sentiment in the market. Investors are likely reallocating their portfolios, leading to a sell-off in Chemours Co shares despite the overall market's slight downturn. This indicates a shift in investor focus, potentially away from chemical companies.
As Chemours Co continues to face pressure, it will be important to monitor any upcoming developments or news that could impact its performance. The current market environment may lead to further volatility in the stock as investors reassess their positions.
Wall Street analysts forecast CC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CC is 16.14 USD with a low forecast of 13.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast CC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CC is 16.14 USD with a low forecast of 13.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 15.110
Low
13.00
Averages
16.14
High
19.00
Current: 15.110
Low
13.00
Averages
16.14
High
19.00
Truist
Buy
maintain
$18 -> $21
2026-01-21
Reason
Truist
Price Target
$18 -> $21
AI Analysis
2026-01-21
maintain
Buy
Reason
Truist raised the firm's price target on Chemours to $21 from $18 and keeps a Buy rating on the shares. The firm adjusted targets in the chemicals group as part of its Q4 earnings preview. The analyst says demand growth for the group will be limited in 2026 given the "low-growth" macro environment. Truist expects relative strength to continue for the companies with exposure to AI and data centers.
BMO Capital
John McNulty
Outperform
maintain
$18 -> $20
2026-01-19
Reason
BMO Capital
John McNulty
Price Target
$18 -> $20
2026-01-19
maintain
Outperform
Reason
BMO Capital analyst John McNulty raised the firm's price target on Chemours to $20 from $18 and keeps an Outperform rating on the shares after the company sold its Taiwan TiO2 site for $360M. The "sizable windfall" is a "meaningful positive" for Chemours, the analyst tells investors in a research note. BMO expects the proceeds to go toward debt reduction, providing a "liquidity cushion" for future PFAS settlements. The firm says the sale should help investors "get comfortable" that Chemours has enough cash to fund future growth opportunities going forward.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CC
Unlock Now
RBC Capital
Outperform
maintain
$16 -> $18
2026-01-16
Reason
RBC Capital
Price Target
$16 -> $18
2026-01-16
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Chemours to $18 from $16 and keeps an Outperform rating on the shares as part of a broader research note previewing Q4 for Commodity Chemicals as part of a broader research note previewing Q4 for Commodity Chemicals. Higher raw material costs and slow demand in Europe/Asia remain near-term headwinds, but TiO2 margins should improve, the analyst tells investors in a research note. The phase-out of high-GWP Hydrofluorocarbon refrigerants over the next 10-20 years should sustain demand growth for low-GWP hydrofluoroolefins into cooling and refrigerant applications, RBC added.
JPMorgan
Neutral
downgrade
$15 -> $13
2025-12-03
Reason
JPMorgan
Price Target
$15 -> $13
2025-12-03
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Chemours to $13 from $15 and keeps a Neutral rating on the shares.
About CC
The Chemours Company provides industrial and specialty chemical products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. The Company’s segments include Titanium Technologies, Thermal & Specialized Solutions and Advanced Performance Materials. The Titanium Technologies segment is a provider of titanium dioxide pigment, a premium white pigment used to deliver whiteness, brightness, opacity and protection in various applications. The Thermal & Specialized Solutions segment is a provider of refrigerants, thermal management solutions, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment is a provider of high-end polymers and advanced materials. Its flagship products include brands such as Opteon, Freon, Ti-Pure, Nafion, Teflon, Viton, and Krytox. The Company serves over 2,700 customers in approximately 110 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
